Akero Therapeutics (AKRO) had the highest return between September 1, 2022 and October 31, 2022 by a US stock with a market cap of $2B+, returning 252.5%.
| ASSET | DATE | % RETURN |
|---|---|---|
Akero Therapeutics (AKRO) | 9/1/2022 - 10/31/2022 | 252.46% |
Biohaven Pharmaceutical (BHVN) | 9/1/2022 - 10/31/2022 | 176.17% |
Immunovant (IMVT) | 9/1/2022 - 10/31/2022 | 120.91% |
Nuvalent (NUVL) | 9/1/2022 - 10/31/2022 | 111.55% |
Ideaya Biosciences (IDYA) | 9/1/2022 - 10/31/2022 | 70.61% |
Janux Therapeutics (JANX) | 9/1/2022 - 10/31/2022 | 69.92% |
Vaxcyte (PCVX) | 9/1/2022 - 10/31/2022 | 66.96% |
Wave Life Sciences (WVE) | 9/1/2022 - 10/31/2022 | 64.6% |
Oceaneering International (OII) | 9/1/2022 - 10/31/2022 | 59.16% |
Intapp (INTA) | 9/1/2022 - 10/31/2022 | 57.17% |
Tidewater (TDW) | 9/1/2022 - 10/31/2022 | 53.67% |
Medpace (MEDP) | 9/1/2022 - 10/31/2022 | 52.51% |
Weatherford International (WFRD) | 9/1/2022 - 10/31/2022 | 50.09% |
DexCom (DXCM) | 9/1/2022 - 10/31/2022 | 47.85% |
International Seaways (INSW) | 9/1/2022 - 10/31/2022 | 46.28% |
Biogen (BIIB) | 9/1/2022 - 10/31/2022 | 45.53% |
Siriuspoint (SPNT) | 9/1/2022 - 10/31/2022 | 43.95% |
Avis Budget (CAR) | 9/1/2022 - 10/31/2022 | 43.74% |
Keros Therapeutics (KROS) | 9/1/2022 - 10/31/2022 | 43.21% |
New Gold (NGD) | 9/1/2022 - 10/31/2022 | 42.84% |
Wingstop (WING) | 9/1/2022 - 10/31/2022 | 42.03% |
Roivant Sciences (ROIV) | 9/1/2022 - 10/31/2022 | 41.99% |
Torm PLC Class A (TRMD) | 9/1/2022 - 10/31/2022 | 41.51% |
YPF Sociedad Anonima (YPF) | 9/1/2022 - 10/31/2022 | 39.67% |
Schlumberger (SLB) | 9/1/2022 - 10/31/2022 | 39.21% |
